Sympathetic

TCT 2023: The Efficacy and Safety of the SMART Trial Presented by World Renowned Expert

Retrieved on: 
금요일, 11월 10, 2023
Hypertension, Safety, SAN, RDN, Patient, ReCore, TCT, Sympathetic, Pharmaceutical industry, Medtronic

The joint SMART Study Investigators-Felix Mahfoud presentation attracted substantial interest and admiration from the audience at the conference.

Key Points: 
  • The joint SMART Study Investigators-Felix Mahfoud presentation attracted substantial interest and admiration from the audience at the conference.
  • The SMART Study enrolled 220 patients with uncontrolled hypertension at a 1:1 ratio into msRDN and Sham groups between November 2016 and February 2022.
  • The results demonstrated the safety and efficacy of renal msRDN to treat uncontrolled hypertension via only four ablations on each side of the renal main artery.
  • Given this context, RDN was one of the central themes and most hotly pursued topics during the TCT conference this year.

EuroPCR 2023 | 6 Month Outcome of the SMART Study: satisfactory BP control achieved with reduced medication burden

Retrieved on: 
금요일, 5월 19, 2023
Late, Feedback, RCT, Sympathetic, Research, RDN, Hypertension, BP, OSBP, Patient, Denervation, 24 Hours, SMART, Treatment, Pharmaceutical industry

It demonstrates that msRDN can effectively control blood pressure while greatly reducing the dosage of antihypertensive drugs.

Key Points: 
  • It demonstrates that msRDN can effectively control blood pressure while greatly reducing the dosage of antihypertensive drugs.
  • In the 6 months follow-up with a strict drug regimen, the msRDN group demonstrated effective blood pressure control.
  • OSBP control rate of the msRDN group was 95% with significantly reduced drug burden compared to the sham group.
  • The result is a resounding prove that patients in the msRDN group can achieve satisfactory BP control with markedly lower anti-hypertensive drug dosage.